EMA Recommends Extension of Therapeutic Indications for Cetuximab By Ogkologos - August 14, 2026 10 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib Source RELATED ARTICLESMORE FROM AUTHOR No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC MOST POPULAR FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... April 8, 2026 Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... July 4, 2024 Immunotherapy Combinations for Treating Metastatic Melanoma and Using Technology to Find... November 15, 2021 Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... August 31, 2021 Load more HOT NEWS Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for... Mom Fighting Breast Cancer Says Her Haunted House Is Something To... “If there is an under-representation of ethnic minority communities, there will... Study presents an AI-guided approach to target cancer antigens
